title: Purinergic receptors in tubulointerstitial inflammatory cells: a pathophysiological mechanism of salt-sensitive hypertension.
abstract: Recent studies have suggested that both the tubulointerstitial inflammatory cells and the activation of purinergic receptors integrate common mechanisms that result in salt-sensitive hypertension. The basis of this hypothesis is that renal endothelial cells release ATP in response to shear stress in the setting of hypertension. It has been demonstrated that the over-expression and activation of the P2X7, P2Y12 and P2X1 receptors favour the elevation of blood pressure induced by high-salt intake. In addition, the release of interleukins and inflammatory mediators in the tubulointerstitial area appears to be related to the activation of these receptors. Renal vasoconstriction and tubulointerstitial injury develop as a result, which increase sodium reabsorption by epithelial cells. Consistent with these effects, the reduction of tubulointerstitial inflammation caused by immunosuppressants, such as mycophenolate mofetil, prevents the development of salt-sensitive hypertension. Also, P2X7-receptor knockout mice develop minor renal injury when hypertension is induced via the administration of deoxycorticosterone acetate and a high-salt diet. In the setting of angiotensin II-induced hypertension, which is an early stage in the development of salt-sensitive hypertension, an acute blockade with the specific, non-selective P2 antagonist pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid prevented the renal vasoconstriction induced by angiotensin II. In addition, it normalized glomerular haemodynamics and restored sodium excretion to control values. These findings suggest that chronic administration of P2 purinergic antagonists may prevent the deleterious effects of purinergic receptors during the development of salt-sensitive hypertension.
authors: Renal Physiopathology Laboratory, Department of Nephrology, Instituto Nacional de Cardiología Ignacio Chávez, México City, Mexico.
authors: M
authors: M
authors: Franco
authors: R
authors: R
authors: Bautista-Pérez
authors: O
authors: O
authors: Pérez-Méndez
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D042783:Endothelial Cells / Q000378:metabolism* / Q000473:pathology; D006977:Hypertension, Renal / Q000378:metabolism* / Q000473:pathology; D007668:Kidney / Q000378:metabolism* / Q000473:pathology; D011983:Receptors, Purinergic / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology
chemical_list: D011983:Receptors, Purinergic; D000255:Adenosine Triphosphate
keywords: angiotensin II; micropuncture; purinergic receptor antagonists; purinergic receptors; pyridoxalphosphate-6-azophenyl-2’,4’-disulfonic acid; renal inflammation